NanoViricides Wins DR Congo Approval for Phase II NV-387 Oral Gummies Trial
NNVC•NanoViricides received DR Congo Pillar Committee approval to initiate a Phase II trial of NV-387 oral gummies for Bundibugyo ebolavirus, addressing 1,561 confirmed cases and 506 deaths as of July 6. The oral broad-spectrum antiviral candidate could fill a critical treatment gap in resource-limited settings.
1. Trial Approval and Setup
NanoViricides has obtained Pillar Committee approval in DR Congo to commence a Phase II clinical trial of NV-387 oral gummies against the Bundibugyo ebolavirus. The company has engaged a renowned principal investigator and a regional university partner following regulatory clearances.
2. Outbreak Context
DR Congo has logged 1,561 confirmed cases and 506 deaths from Bundibugyo ebolavirus as of July 6, with no approved therapies available. The rare BDBV variant appears recently introduced from animal reservoirs, intensifying outbreak containment challenges.
3. NV-387 Oral Gummy Advantages
NV-387 is a broad-spectrum antiviral designed to mimic host cell features required by viruses, making escape unlikely despite viral mutations. Its orally dissolvable gummy format simplifies dosing in resource-limited settings and outperforms infusion-based therapies in scalability.
4. Next Steps and Financial Implications
Next steps include submissions to DR Congo’s National Ethics Committee and regulatory agency for trial activation, leveraging prior ACOREP approval for an Mpox trial. Successful Phase II results could accelerate market entry and drive significant value for NanoViricides.
